Cameroon vs Tajikistan: Access to anti-retroviral drugs, female
Cameroon
95.0%
in 2024
Tajikistan
95.0%
in 2024
Cameroon rank
19th
Tajikistan rank
19th
Access to anti-retroviral drugs, female over time
- Cameroon
- Tajikistan
How they compare
Cameroon currently reports 95.0% against 95.0% in Tajikistan, a difference of 0.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Tajikistan ahead.
Cameroon ranks 19th and Tajikistan ranks 19th of 141 countries.
Cameroon has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cameroon | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.2% | 0.7% | 3.5% | Cameroon |
| 2010s | 38.0% | 29.8% | 8.2% | Cameroon |
| 2020s | 86.6% | 83.4% | 3.2% | Cameroon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Cameroon or Tajikistan?
- Cameroon, at 95.0% against 95.0% in Tajikistan as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Cameroon and Tajikistan?
- 0.0%, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Tajikistan?
- 25 years are reported by both, from 2000 to 2024.
- How do Cameroon and Tajikistan rank globally for access to anti-retroviral drugs, female?
- Cameroon ranks 19th and Tajikistan ranks 19th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.